VOLUME 7 NUMBER 1 • MARCH 2010
33
Loboz KK, Shenfield GM. Drug combinations and impaired renal function – the
8.
‘triple whammy’. Br J Clin Pharmacol 2005;
59
: 239–243, doi:10.1111/j.0306-
5251.2004.2188.x.
NICE Clinical Guideline 34. Hypertension: management of hypertension in adults in
9.
primary care. June 2006.
Nephrology Pharmacy Associates, 2004. Kidney disease 04. A handbook of clinical
10.
practice guidelines (Online). Available at
-
loads/KidneyDisease.pdf (Accessed 02.02.09).
Campoy S, Elwell R. Pharmacology & CKD: How chronic kidney disease and its
11.
complications alter drug response. Am J Nurs 2005;
105
(9): 60–71.
Lesho E, Udvari-Nagy SV, Saullo L
12.
et al. Common errors in internal medicine: treat-
ing hypertension in patients with elevated serum creatinine. Federal Practitioner
2003;
20
(9): 11–15, 31.
Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in
13.
Cardiovascular Disease and the Council for High Blood Pressure Research of the
American Heart Association. Renal considerations in angiotensin converting en-
zyme inhibitor therapy: a statement for health-care professionals from the Council
on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure
Research of the American Heart Association. Circulation 2001;
104
(16): 1985–
1991, doi:10.1161/hc4101.096153.
Gupta R, Birnbaum Y, Uretsky BF. The renal patient with coronary artery disease:
14.
current concepts and dilemmas. J Am Coll Cardiol 2004;
44
(7): 1343–1353.
Frye RF, Matze GR. Drug therapy and individualization for patients with renal insuf-
15.
ficiency. In: DiPiro JT et al, editors. Pharmacotherapy: A Pathophysiologic Approach.
5th ed. New York: McGraw-Hill; 2002: 939–952.
Dykeman-Sharpe J. Over-the-counter remedies in chronic renal insufficiency: risks
16.
versus benefits. Cannt J 2003;
13
(2): 17–28.
Davidson AM, Cameron JS, Grunfeld JP
17.
et al. Oxford Textbook of Nephrology. Sec-
ond ed. Oxford. Oxford University Press, 1998.
WheltonA.Nephrotoxicity of nonsteroidal anti-inflammatory drugs:physiologic foun-
18.
dations and clinical implications. Am J Med 1999;
106
: 13S–24S, doi:10.1016/
S0002-9343(99)00113-8.
Harris RC. Cyclooxygenase-2 inhibition and renal physiology.
19.
Am J Cardiol 2002;
89
(suppl): 10D–17D, doi:10.1016/S0002–9149(02)02232-4.
Huerta C, Castellsague J, Varas-Lorenzo C, Garc’a Rodr’guez LA. Nonsteroidal anti-
20.
inflammatory drugs and risk of ARF in the general population. Am J Kidney Dis
2005;
45
: 531–539, doi:10.1053/j.ajkd.2004.12.005.
Galli G, Panzetta G. Do non-steroidal anti-inflammatory drugs and Cox-2 selective
21.
inhibitors have different renal effects? J Nephrol 2002;
15
: 480–488.
Glucophage. Summary of product characteristics. Merck Serono, October 2004.
22.
Casas JP, Chua W, Loukogeorgakis S,
23.
et al. Effect of inhibitors of the renin-angi-
otensin system and other antihypertensive drugs on renal outcomes: systematic
review and meta-analysis. Lancet 2005;
366
: 2026–2033, doi:10.1016/S0140-
6736(05)67814-2.
Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic aci-
24.
dosis with metformin used in type 2 diabetes. Cochrane Database Syst Rev 2006;
(1): CD002967, 10.1002/14651858.CD002967.pub2.
Snyder RW, Berns JS. Use of insulin and oral hypoglycaemic medications in pa-
25.
tients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;
17
(5):
365–370, doi:10.1111/j.0894–0959.2004.17346.x.
Ashley C, Currie A.
26.
The Renal Drug Handbook. Second edition, Oxford Radcliffe
Press, 2004.
SA JOURNAL OF DIABETES & VASCULAR DISEASE
Hands On
Two-year update: liraglutide patients lose 5% of their body weight
A
two-year update of a trial compar-
ing liraglutide with a sulfonylurea in
patients with type 2 diabetes demonstrated
that liraglutide continued to control hyper-
glycaemia better than a sulfonylurea, with-
out increasing the risk for hypoglycaemia.
Results of two years of data were pre-
sented at the International Diabetes Feder-
ation (IDF) 20th World Diabetes Congress.
Presenter and lead author Alan J Garber,
MD, PhD, FACE, stated that liraglutide
(Novo Nordisk) is a human glucagon-like
peptide-1 analogue that ‘has insulin stimu-
latory effects in the presence of glucose,
has glucagon-suppressive effects in the
absence of hypoglycaemia, retards gastric
emptying, and diminishes appetite’.
‘It sounds like an ideal combination
for overweight people with type 2 diabe-
tes, and it is. They lose weight, they don’t
get hypoglycaemic, and their sugar levels
come down’, said Dr Garber, who is from
the Baylor College of Medicine Faculty
Center in Houston, Texas, and is secretary
of the American Association of Clinical
Endocrinologists.
In the Liraglutide Effect and Action in
Diabetes-3 (LEAD-3) study, 746 patients
with type 2 diabetes and a body mass index
(BMI) of 45 kg/m
2
or less were randomised
to receive once-daily liraglutide (1.2 or 1.8
mg) or the sulfonylurea drug glimepiride (8
mg) for 52 weeks. The primary endpoint
was change in proportion of glycosylated
haemoglobin (HbA
1c
). At the outset of the
trial, all patients had their diabetes con-
trolled with diet and exercise alone, or by
taking oral diabetic agents at half or less of
the maximal dose.
After 20 weeks, those on liraglutide lost
more weight than those on the placebo.
Participants on the highest dose of liraglu-
tide lost 15 lbs (6.8 kg), compared with 6
lbs (2.7 kg) on the placebo and 9 lbs (4 kg)
on orlistat. Three-quarters of the subjects
on the highest dosage of liraglutide lost
5% or more of their body weight.
The medication also reduced blood
pressure at all dosages. At the three high-
est dosages, liraglutide reduced symptoms
of pre-diabetes (blood glucose levels above
Diabetes News
